These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6218942)

  • 21. [Analysis of plasminogen activator in human plasma using the method of fibrin/celite column chromatography--with special reference to the determination of fibrin adsorbable tissue-plasminogen activator by ELISA].
    Ieko M
    Hokkaido Igaku Zasshi; 1985 Nov; 60(6):834-47. PubMed ID: 4085966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Releasing of plasminogen-activator from the kidney to the blood (author's transl)].
    Nakata A; Hagita M; Okamoto U
    Nihon Seirigaku Zasshi; 1978 Nov; 40(11):419-26. PubMed ID: 155161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
    Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
    Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV; Frank JD; Craft TJ; Sundboom JL; Smith GF
    J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion.
    Hayashido Y; Hamana T; Ishida Y; Shintani T; Koizumi K; Okamoto T
    Oncol Rep; 2007 Feb; 17(2):417-23. PubMed ID: 17203182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma.
    Dooijewaard G; de Boer A; Turion PN; Cohen AF; Breimer DD; Kluft C
    Thromb Haemost; 1991 Jan; 65(1):82-6. PubMed ID: 1902597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of the inhibition of plasmin in acidified human plasma.
    Lijnen HR; Maes M; Castel M; Samama M; Collen D
    Thromb Haemost; 1982 Dec; 48(3):257-9. PubMed ID: 6219470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
    Zhang X; Chaudhry A; Chintala SK
    Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
    Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
    Agents Actions Suppl; 1992; 38 ( Pt 2)():320-9. PubMed ID: 1462839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot.
    Takada A; Ito T; Takada Y
    Thromb Haemost; 1980 Feb; 43(1):20-3. PubMed ID: 6447383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
    Kramer MD; Reinartz J
    J Clin Invest; 1993 Aug; 92(2):978-83. PubMed ID: 7688770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-induced release of plasminogen activator from human blood platelets.
    Kahn NN; Bauman WA; Sinha AK
    Am J Physiol; 1995 Jan; 268(1 Pt 2):H117-24. PubMed ID: 7530914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
    Carpenter SL; Mathew P
    Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Features of the interaction between alpha2-antiplasmin and plasminogen/plasmin].
    Hrynenko TV; Iusova OI; Zadorozhna MB; Makohonenko IeM
    Ukr Biokhim Zh (1999); 2002; 74(6):83-90. PubMed ID: 12924019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of alpha 2-antiplasmin in the inhibition of clot lysis in newborns and adults.
    Ries M; Klinge J; Rauch R; Keuper H; Harms D
    Biol Neonate; 1996; 69(5):298-306. PubMed ID: 8790908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis.
    Gissler HM; Frank R; Kramer MD
    Br J Dermatol; 1993 Jun; 128(6):612-8. PubMed ID: 7687853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator in acute myeloid leukaemic marrows: u-PA in contrast to t-PA in normal marrow.
    McWilliam N; Robbie L; Booth N; Bennett B
    Br J Haematol; 1998 Jun; 101(4):626-31. PubMed ID: 9674732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD; Gram J; Jespersen J
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells].
    Zhabin SG; Zorin NA; Musatov MI
    Vopr Med Khim; 1995; 41(3):34-7. PubMed ID: 8585176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolytic system in adolescents: response to venous occlusion stress tests.
    Monagle P; Chan AK; Albisetti M; Vegh P; Andrew M; Mitchell L
    Pediatr Res; 2003 Feb; 53(2):333-7. PubMed ID: 12538795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.